AJJ MEDTECH HOLDINGS LIMITED
(Company Registration No. 198403368H)
(Incorporated in the Republic of Singapore)

HIT-X2 MULTIFUNCTIONAL HUMANOID ELDERCARE ROBOT FOR HOME USE UPDATE ON COLLABORATIVE DEVELOPMENT AND COMMERCIALISATION

The Board of Directors (the "**Board**") of AJJ Medtech Holdings Limited (the "**Company**", and together with its subsidiaries, the "**Group**") wishes to announce that its wholly-owned subsidiary, AJJ Healthcare Management Pte. Ltd. ("**AJJ Healthcare**"), entered into a supplemental agreement for the collaborative development of the HIT-X2 home robot (the "**Supplemental Agreement**") with Hangzhou Huaxi Intelligent Technology Co., Ltd. ("**Huaxi Intelligent**") on 2 November 2026.

1. Cooperation Progress and Product Notification

The Supplemental Agreement builds on the legally binding memorandum of understanding signed by the parties on 10 October 2025. The collaboration covers the development, localisation and market promotion of HIT-X2, a multifunctional humanoid eldercare robot for home use. Its geographical scope comprises Singapore and such other countries and regions as the parties may separately agree in writing.

On 12 October 2025, the Company announced that AJJ Healthcare and Huaxi Intelligent had established a collaboration for the development and operation of humanoid eldercare robots. The HIT-X2 collaboration represents a further milestone following the parties' cooperation on HIT-1, extending their product portfolio into home-based care.

The Class A medical device product notification for HIT-X2 (identified in the HSA records as AJJ-HIT-X2) was completed with Singapore's Health Sciences Authority ("**HSA**") on 20 October 2026 under notification number MDPN261020P0001 where AJJ Healthcare is listed as the product owner and the notifying entity. Class A medical devices are subject to product notification and are exempt from product registration in Singapore.

2. Product Positioning and Technological Features

HIT-X2 is designed as an embodied AI-powered home care platform. Its 24 eldercare functional modules are organised into 15 core functions and supporting services for users. The platform brings together multimodal interaction, cross-device coordination and multi-role AI agents within an integrated architecture for companionship, health information management, home safety and access to care services. Its technological features emphasise contextual awareness, personalised interaction and coordination across functions.

For access to medical services, the platform is intended to connect users to remote consultations with doctors through appropriately qualified healthcare service partners, with links to medication delivery and medication management services. The availability of these services will depend on the relevant partner arrangements and applicable regulatory requirements.

3. Singapore Business Operations and Commercialisation Preparations

Huaxi Intelligent will lead product and technology development and provide the agreed technical support. AJJ Healthcare will lead local needs research, application scenario design, localisation coordination and market development in Singapore. The scope of work, technical requirements and responsibilities of each party for specific projects will be separately confirmed in writing.

AJJ Healthcare is responsible for carrying out both online and offline HIT-X2 business activities in Singapore. It has completed the development of its B2C website for individual and household consumers and is responsible for the website, local sales and service operations.

Current commercialisation preparations focus on adapting and validating product configurations and local usage workflows, deploying cloud infrastructure and AI services, and arranging delivery, training and after-sales support. Launch configurations will take into account technological maturity, safety validation, applicable regulatory requirements and service partner arrangements. Additional functions and services may be introduced in phases.

Following this announcement, the Group plans to conduct technology demonstrations, market promotion activities and discussions with prospective partners. The timing of HIT-X2's official launch and the commencement of pre-orders, together with the available product configurations, functions and services, pricing, payment and delivery arrangements, will be announced separately.

Company website: https://www.ajjmedtech.com.sg/

B2C website: ajj-hit-x2.com

4. Care Value and Responsible Governance

The Group believes that integrating daily interaction, family communication and access to care resources within a home care platform can support older persons with living in familiar surroundings. This collaboration provides a foundation for expanding the product and service offering for household users and exploring continuity of care across institutional, community and home settings.

Deployment requirements will encompass privacy protection, appropriate consent, access controls, data security, and human oversight and intervention. The respective responsibilities of those involved in operating and supervising the robot and AI systems, responding to alerts and delivering services will be clearly defined. Personal data will be handled in accordance with Singapore's Personal Data Protection Act 2012 and other applicable requirements, including where data are accessed from or transferred outside Singapore.

Health-related functions are intended to support observation and care coordination and do not replace professional diagnosis or treatment. Medical services will be provided by appropriately qualified institutions and doctors.

5. Financial Impact and Cautionary Statement

The parties will implement the commercial arrangements for this collaboration in accordance with the Supplemental Agreement and the relevant written agreements. The financial impact will depend on the product configurations and pricing ultimately offered, the volume and timing of deliveries, customer adoption, and the associated development and operating expenditure. Given these variables, the Group is not yet in a position to reliably quantify that impact.

The Board wishes to highlight that the subsequent development, deployment and commercialisation plans described in this announcement involve forward-looking statements. Their implementation timetable and commercial outcomes remain subject to uncertainties. Such plans should not be construed

as a forecast or assurance of future customer orders, sales revenue, profitability or the Group's financial performance.

The Company will make further announcements on material developments in accordance with the applicable disclosure requirements of the Catalist Rules.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company. Persons who are in doubt about the action they should take should consult their professional advisers.

BY ORDER OF THE BOARD

Dr Tan Wei Jie

Chief Executive Officer and Executive Director

Date: 05 November 2026

---

*This document has been reviewed by the Company's sponsor, Evolve Capital Advisory Private Limited (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this document, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this document.*
The contact person for the Sponsor is Mr. Jerry Chua (Tel: (65) 6241 6626), at 160 Robinson Road, #20-01/02, SBF Centre, Singapore 068914.